Kyowa Kirin Co., Ltd.
4151
Classifica tra le azioni
#2440
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Prezzo delle azioni
$15.33
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$8.02B
Variazione (1 giorno)
2.04%
Variazione (1 anno)
3.44%
Paese
JP
Scambia Kyowa Kirin Co., Ltd. (4151)
Categoria
Healthcare
Margine operativo per Kyowa Kirin Co., Ltd. (4151)
Margine operativo al October 2026 TTM: 24.38%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Kyowa Kirin Co., Ltd., il margine operativo attuale (TTM) è 24.38%. Alla fine del 2024, il margine operativo era 18.54%.
Storico del margine operativo per Kyowa Kirin Co., Ltd. da 2001 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | 24.38% | 18.41% |
| 2025 | 20.59% | 11.06% |
| 2024 | 18.54% | -14.44% |
| 2023 | 21.67% | 4.79% |
| 2022 | 20.68% | 19.12% |
| 2021 | 17.36% | -6.31% |
| 2020 | 18.53% | 23.70% |
| 2019 | 14.98% | -30.81% |
| 2018 | 21.65% | 32.50% |
| 2017 | 16.34% | 77.22% |
| 2016 | 9.22% | -23.23% |
| 2015 | 12.01% | 10.69% |
| 2014 | 10.85% | -28.62% |
| 2013 | 15.20% | -4.28% |
| 2012 | 15.88% | -35.84% |
| 2011 | 24.75% | 125.41% |
| 2010 | 10.98% | 20.13% |
| 2009 | 9.14% | -9.05% |
| 2008 | 10.05% | 18.10% |
| 2007 | 8.51% | 17.87% |
| 2006 | 7.22% | -22.62% |
| 2005 | 9.33% | 21.33% |
| 2004 | 7.69% | 47.04% |
| 2003 | 5.23% | -2.79% |
| 2002 | 5.38% | 13.98% |
| 2001 | 4.72% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 49.72% | -97.96% |
US
|
|
| 25.70% | -98.95% |
US
|
|
| 29.32% | -98.80% |
US
|
|
| 26.59% | -98.91% |
CH
|
|
| 16.65% | -99.32% |
US
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.